Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma

[1]  S. Nakajima,et al.  Current status of immune checkpoint inhibitors for gastric cancer , 2020, Gastric Cancer.

[2]  Wei Guo,et al.  Insight Into the Role of Autophagy in Osteosarcoma and Its Therapeutic Implication , 2019, Front. Oncol..

[3]  M. Raftery,et al.  The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance , 2019, Front. Cell. Infect. Microbiol..

[4]  G. Carle,et al.  Role of autophagy in osteosarcoma , 2019, Journal of bone oncology.

[5]  Z. Duan,et al.  Advances in immune checkpoint inhibitors for bone sarcoma therapy , 2019, Journal of bone oncology.

[6]  J. Gong,et al.  Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination , 2018, Journal of Immunotherapy for Cancer.

[7]  T. Schumacher,et al.  Regulation and Function of the PD-L1 Checkpoint. , 2018, Immunity.

[8]  C. Antonescu,et al.  Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. , 2018, The Lancet. Oncology.

[9]  J. Crowley,et al.  Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[10]  L. Zitvogel,et al.  Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy. , 2017, Cancer research.

[11]  T. Fujiwara,et al.  Impact of Autophagy in Oncolytic Adenoviral Therapy for Cancer , 2017, International journal of molecular sciences.

[12]  M. Canale,et al.  Immune Checkpoints as a Target for Colorectal Cancer Treatment , 2017, International journal of molecular sciences.

[13]  M. Coffey,et al.  Prime-boost using Separate Oncolytic Viruses in Combination with Checkpoint Blockade Improves Anti-tumor Therapy , 2016, Gene Therapy.

[14]  T. Fujiwara,et al.  Ablation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas , 2016, Scientific Reports.

[15]  D. Felsher,et al.  MYC regulates the antitumor immune response through CD47 and PD-L1 , 2016, Science.

[16]  Liliana Vásquez,et al.  Analysis of Prognostic Factors in High-Grade Osteosarcoma of the Extremities in Children: A 15-Year Single-Institution Experience , 2016, Front. Oncol..

[17]  H. Kaufman,et al.  Oncolytic viruses: a new class of immunotherapy drugs , 2015, Nature Reviews Drug Discovery.

[18]  J. Sosman,et al.  Nivolumab in melanoma: latest evidence and clinical potential , 2015, Therapeutic advances in medical oncology.

[19]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[20]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[21]  J. Fueyo,et al.  Healing after death: antitumor immunity induced by oncolytic adenoviral therapy , 2014, Oncoimmunology.

[22]  D. Bartlett,et al.  Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity , 2014, Front. Oncol..

[23]  C. Graham,et al.  A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. , 2014, Cancer research.

[24]  D. Bartlett,et al.  Oncolytic viruses as therapeutic cancer vaccines , 2013, Molecular Cancer.

[25]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[26]  Laurence Zitvogel,et al.  Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.

[27]  T. Fujiwara,et al.  Dual Programmed Cell Death Pathways Induced by p53 Transactivation Overcome Resistance to Oncolytic Adenovirus in Human Osteosarcoma Cells , 2013, Molecular Cancer Therapeutics.

[28]  A. Fedenko,et al.  A Meta-Analysis of Osteosarcoma Outcomes in the Modern Medical Era , 2012, Sarcoma.

[29]  F. Di Virgilio,et al.  Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice , 2011, Science.

[30]  R. DePinho,et al.  A BAC transgenic reporter recapitulates in vivo regulation of human telomerase reverse transcriptase in development and tumorigenesis , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  T. Fujiwara,et al.  Preclinical Evaluation of Telomerase-Specific Oncolytic Virotherapy for Human Bone and Soft Tissue Sarcomas , 2011, Clinical Cancer Research.

[32]  T. Fujiwara,et al.  Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. , 2010, Cancer research.

[33]  N. Senzer,et al.  A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  Y. Iwamoto,et al.  Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J , 2009, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.

[35]  T. Fujiwara,et al.  Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer , 2009, Molecular Cancer Therapeutics.

[36]  G. Mills,et al.  Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells , 2008, Gene Therapy.

[37]  H. Kijima,et al.  Establishment of transplantable murine osteosarcoma cell line with endochondral ossification. , 2008, Anticancer research.

[38]  S. Lowe,et al.  Adenovirus E1A targets p400 to induce the cellular oncoprotein Myc , 2008, Proceedings of the National Academy of Sciences.

[39]  T. Fujiwara,et al.  Establishment of biological and pharmacokinetic assays of telomerase‐specific replication‐selective adenovirus , 2008, Cancer science.

[40]  F. Schmidt.  Meta-Analysis , 2008 .

[41]  Piero Picci,et al.  Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy , 2006, Cancer.

[42]  C. Hellerbrand,et al.  PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosis , 2006 .

[43]  C. Englert,et al.  A novel transgenic mouse model reveals humanlike regulation of an 8-kbp human TERT gene promoter fragment in normal and tumor tissues. , 2005, Cancer research.

[44]  S. Kyo,et al.  Telomerase-Specific Replication-Selective Virotherapy for Human Cancer , 2004, Clinical Cancer Research.

[45]  H. Tsuchiya,et al.  Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  M. Link,et al.  Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  S. Tsuchida,et al.  A Murine Osteosarcoma Cell Line with a Potential to Develop Ossification upon Transplantation , 2001, Japanese journal of cancer research : Gann.

[49]  P. Meltzer,et al.  Metastasis-associated differences in gene expression in a murine model of osteosarcoma. , 2001, Cancer research.

[50]  J. Bergelson,et al.  Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5 , 1997, Science.

[51]  G. Nemerow,et al.  Integrins α v β 3 and α v β 5 promote adenovirus internalization but not virus attachment , 1993, Cell.

[52]  G. Blair,et al.  Restricted replication of human adenovirus type 5 in mouse cell lines. , 1989, Virus research.

[53]  M. Coffey,et al.  Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[54]  T. Fujiwara,et al.  Oncolytic adenovirus-induced autophagy: tumor-suppressive effect and molecular basis. , 2013, Acta medica Okayama.

[55]  L. Zitvogel,et al.  Molecular characteristics of immunogenic cancer cell death , 2008, Cell Death and Differentiation.

[56]  C. Hellerbrand,et al.  PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. , 2006, Journal of hepatology.

[57]  L. Helman,et al.  An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential , 2004, Clinical & Experimental Metastasis.